Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research and development. Global regulatory changes favor Indian players. The market is not yet fully recognizing this innovation pivot and the quality of talent driving it. GLP-1 drugs and supply chain diversification also present substantial growth potential.
Indian pharmaceutical companies are transitioning from a generics-focused model to one driven by innovation, a shift expected to unfold until 2035. This transformation presents substantial new opportunities through advanced R&D and global regulatory changes. Despite significant…
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.